These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37575679)

  • 1. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
    Kumar S; Ali I; Abbas F; Khan N; Gupta MK; Garg M; Kumar S; Kumar D
    In Silico Pharmacol; 2023; 11(1):20. PubMed ID: 37575679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico identification and exploration of small molecule coumarin-1,2,3-triazole hybrids as potential EGFR inhibitors for targeting lung cancer.
    Kumar S; Ali I; Abbas F; Shafiq F; Yadav AK; Ghate MD; Kumar D
    Mol Divers; 2024 Mar; ():. PubMed ID: 38470555
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kumar S; Ali I; Abbas F; Rana A; Pandey S; Garg M; Kumar D
    J Biomol Struct Dyn; 2023 Aug; ():1-23. PubMed ID: 37646177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
    Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
    J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Exploration of the Inhibitory Mechanism of Rationally Screened Benzofuran-1,3,4-Oxadiazoles and-1,2,4-Triazoles as Inhibitors of NS5B RdRp Hepatitis C Virus through Pharmacoinformatic Approaches.
    Irfan A; Faisal S; Ahmad S; Saif MJ; Zahoor AF; Khan SG; Javid J; Al-Hussain SA; Muhammed MT; Zaki MEA
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Imana SN; Ningsih EG; Tambunan USF
    Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel quinazoline-chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies.
    Tokalı FS; Şenol H; Yetke Hİ; Hacıosmanoğlu-Aldoğan E
    Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300423. PubMed ID: 37736677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening of acetylcholinesterase inhibitors through pharmacophore-based 3D-QSAR modeling, ADMET, molecular docking, and MD simulation studies.
    Kumar H; Datusalia AK; Khatik GL
    In Silico Pharmacol; 2024; 12(1):13. PubMed ID: 38370859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing and
    Patil SM; Shashikant B
    Curr Drug Discov Technol; 2023; 20(6):47-59. PubMed ID: 37291789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Docking of Medicinal Herbs Against P. gingivalis for Chronic Periodontitis Intervention.
    Saini RS; Vaddamanu SK; Dermawan D; Bavabeedu SS; Khudaverdyan M; Mosaddad SA; Heboyan A
    Int Dent J; 2024 Aug; ():. PubMed ID: 39127518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
    Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
    Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
    Xiang M; Lei K; Fan W; Lin Y; He G; Yang M; Chen L; Mo Y
    Drug Des Devel Ther; 2013; 7():789-839. PubMed ID: 23990708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,2,3-triazole and chiral Schiff base hybrids as potential anticancer agents: DFT, molecular docking and ADME studies.
    Belay Y; Muller A; Mokoena FS; Adeyinka AS; Motadi LR; Oyebamiji AK
    Sci Rep; 2024 Mar; 14(1):6951. PubMed ID: 38521876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
    Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
    3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.